Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer
Status:
Withdrawn
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this research study is to see whether adding bavituximab (an
investigational drug) to the standard chemotherapy drug taxane, will improve the results of
the treatment for HER2-negative metastatic breast cancer.